Drug Profile


Latest Information Update: 14 Aug 2007

Price : $50

At a glance

  • Originator Genaera Corporation
  • Class Antibacterials; Peptide antibiotics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 28 Mar 2001 Magainin Pharmaceuticals is now called Genaera Corporation
  • 03 Aug 2000 An in vitro study has been added to the antimicrobial activity section of Bacterial infections
  • 10 Feb 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top